Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents

Hepatology

Volumn 56, Issue 6, 2012, Pages 2398-2403

  Wedemeyer, Heiner ^a   Jensen, Donald M ^b   Godofsky, Eliot ^c   Mani, Nina ^d,e   Pawlotsky, Jean Michel ^f,g   Miller, Veronica ^e  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c Bach and Godofsky   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e GEORGE WASHINGTON UNIVERSITY   (United States)

^f HENRI MONDOR HOSPITAL   (France)

^g INSERM U955   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; PEGINTERFERON; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL PRACTICE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER; MEDICAL SOCIETY; NOMENCLATURE; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; HEPACIVIRUS; HEPATITIS C; HUMANS; LIMIT OF DETECTION; RNA, VIRAL; TERMINOLOGY AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; VIREMIA;

EID: 84870018201     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25888     Document Type: Article

References (17)

1. Soriano V, Vispo E, Poveda E, Labarga P, Martin-Carbonero L, Fernandez-Montero JV, et al. Directly acting antivirals against hepatitis C virus. J Antimicrob Chemother 2011; 66: 1673-1686.
2. Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376: 1467-1475.
3. Lok A, Gardiner D, Lawitz E, Martorell C, Everson G, Ghalib R, et al. Quadruple therapy with BMS-790052, BMS-650032 and Peg-IFN/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders. Abstract 418. In: EASL; Berlin, Germany; 2011.
4. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264.
5. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
6. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis c virus infection: 2011 practice guidelines by the American Association for the Study of Liver Diseases. HEPATOLOGY 2011; 54: 1433-1444.
7. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
8. Poordad F, McCone J Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
9. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
10. Incivek US Prescribing Information. May 2011; Vertex Pharmaceuticals. Cambridge, MA.
11. Victrelis US Prescribing Information. May 2011; Merck & Co. Whitehouse Station NJ.
12. COBAS AmpliPrep/COBAS TaqMan HCV Test Package Insert. October 2008; Roche Molecular Systems, Branchburg, NJ.
13. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-716.
14. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838.
15. Harrington PR, Zeng W, Naeger LK. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. HEPATOLOGY 2012; 55: 1048-1057.
16. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. HEPATOLOGY 2009; 49: 1335-1374.
17. Jacobson IM, Poordad F, Brown RS Jr., Kwo PY, Reddy KR, Schiff E. Standardization of terminology of virological response in the treatment of chronic hepatitis C: panel recommendations. J Viral Hepatol 2012; 19: 236-243.